Search filters

Filters
Clear All

Phase

  • 16
  • 6
  • 13
  • 19
  • 21
  • 80
  • 44
  • 3
  • 5
  • 73

Found 81 Menstruation trials

A listing of Menstruation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 2
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
99 years or below
All genders
This study seeks to roll over subjects from ISIS 678354-CS3 (the index study; Penn IRB#850921). Patients will receive drug at the dose of 80 mg every 4 weeks (or 50 mg every-4-weeks if their dose was permanently reduced from 80 mg to 50 mg (ISIS 678354 or placebo) in the …
99 years or below
All genders
Phase 2
Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or …
99 years or below
All genders
The main purpose of this study is to see if it is safe to give people 10-1074-LS and 3BNC117-LS and to see if these study drugs cause any side effects. We also want to see how the study drugs affect the level of HIV in the blood when you are …
 Study Evaluating the Efficacy of Synergo  Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo  RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC)
18 years - 99 years
All genders
Phase 3
The objectives of the study are to determine the efficacy and safety of Synergo® RITE and mitomycin C (MMC) in the treatment of carcinoma in situ (CIS) non-muscle invasive bladder cancer in adult patients who didn't respond to 2 courses of treatment with Bacillus Calmette-Guérin (BCG) installations. The Synergo® system …
 ASPEN- A Phase 3  Randomized  Double-Blind  Placebo-Controlled Study to Assess the Efficacy  Safety  and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis
18 years - 85 years
All genders
Phase 3
Interventional
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study. The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the …
99 years or below
All genders
The purpose of this registry is to collect real-time data for those patients who have aortic disease of their ascending (top) aorta and the aortic arch (curved area where the vessels that supply the brain with blood). The current treatment requires open surgery or a hybrid procedure (open surgery with …
 HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
18 years - 85 years
All genders
Phase 3
Interventional
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period.
99 years or below
All genders
The study is being conducted to understand why the skeletal muscle of patients with Heart Failure with Preserved Ejection Fraction (HFpEF) does not work as well as the muscle of individuals without heart failure. This study seeks to understand whether the problem is with blood and oxygen delivery to the …
99 years or below
All genders
Phase 1
Patients with known or suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 20 …